Haemophilus influenzae type b

Phase 2Biologic

Novartis

Haemophilus influenzae type b is one of 37 biologic programs targeting Influenza. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

DiphtheriaActive, not recruiting

InfluenzaPhase 1

Active, not recruiting

DiphtheriaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Haemophilus influenzae type b

Novartis

Phase 2

5 7

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Influenza

NCT07203755

Clinical

Trials by Indication[1]

Influenza5 trials

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Completed· Novartis logo

Novartis·Phase 1·NCT00734565·40 enrolled

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 1·NCT07203755·260 enrolled

Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China

Completed· Novartis logo

Novartis·Phase 3·NCT01044316·670 enrolled

Show 2 more trials

Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Completed· Novartis logo

Novartis·Phase 3·NCT00808392·916 enrolled

Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children

Completed· Novartis logo

Novartis·Phase 4·NCT01404962·764 enrolled

Diphtheria1 trial

Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Completed· Sanofi logo

Sanofi·Phase 2·NCT00771849·103 enrolled

Immunogenicity1 trial

Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

Completed· Novartis logo

Novartis·Phase 3·NCT01226953·660 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Haemophilus influenzae type b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Haemophilus influenzae type b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Haemophilus influenzae type b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Novartis

Haemophilus influenzae type b

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Influenza5 trials

Diphtheria1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News